Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer

SALT LAKE CITY, June 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug...
June 06, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Featured at the 2018 European League Against Rheumatism Annual Meeting

SALT LAKE CITY, June 06, 2018 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that data on the use of the Vectra® DA test...
June 01, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Presents Second Pivotal Validation Study for riskScore™ Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

SALT LAKE CITY, June 01, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from a second major...
May 31, 2018 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at Two Upcoming Investor Conferences

SALT LAKE CITY, May 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two...
May 31, 2018 07:05 ET | Source: Myriad Genetics, Inc.

GeneSight® Guided Treatment Significantly Improves Outcomes for Patients with Major Depression Treated in the Primary Care Setting

New Results from the IMPACT Study to be Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting SALT LAKE CITY, May 31, 2018 (GLOBE NEWSWIRE) -- Assurex Health, a...
May 28, 2018 18:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Signs Definitive Agreement to Acquire Counsyl, Inc.

SALT LAKE CITY, May 28, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive...
May 23, 2018 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Announces Seven New Payer Coverage Decisions for Prolaris®

SALT LAKE CITY, May 23, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced seven new commercial coverage decisions for...
May 15, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting

SALT LAKE CITY, May 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from...
May 08, 2018 06:30 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results

Total Revenues of $193.5 Million GAAP Diluted EPS of $0.16 and Adjusted EPS of $0.31 Up 15 PercentCompany Raises Both Revenue and Adjusted EPS Guidance for Fiscal Year 2018Company Announces Commercial...
May 07, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Landmark Study Shows GeneSight® Test Led to Significant Improvement in Mental Health Outcomes for Patients with Major Depressive Disorder

SALT LAKE CITY, May 07, 2018 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that results from a large, well-controlled...